DNDI-6148 is A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis. DNDI-6148 combines impressive in vivo efficacy (>98% reduction in parasite burden) with pharmaceutical properties suitable for onward development and an acceptable safety profile. DNDI-6148 acts principally through the inhibition of Leishmania cleavage and polyadenylation specificity factor (CPSF3) endonuclease. As a result of these studies and its promising profile, DNDI-6148 has been declared a preclinical candidate for the treatment of VL.
MedKoo Cat#: 465647
Name: DNDI-6148
CAS#: 2243909-59-1
Chemical Formula: C16H14BN5O3
Exact Mass: 335.1190
Molecular Weight: 335.13
Elemental Analysis: C, 57.34; H, 4.21; B, 3.23; N, 20.90; O, 14.32
The following data is based on the product molecular weight 335.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
